Suppr超能文献

日本2型糖尿病患者口服司美格鲁肽后食物偏好的变化:鸭川糖尿病队列研究

Changes in food preferences after oral semaglutide administration in Japanese patients with type 2 diabetes: KAMOGAWA-DM cohort.

作者信息

Hironaka Junya, Ushigome Emi, Kondo Yuriko, Hashimoto Yoshitaka, Osaka Takafumi, Majima Saori, Nakanishi Naoko, Okada Hiroshi, Senmaru Takafumi, Hamaguchi Masahide, Yamazaki Masahiro, Fukui Michiaki

机构信息

Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Department of Diabetology, Kameoka Municipal Hospital, Kyoto, Japan.

出版信息

Diab Vasc Dis Res. 2025 Jan-Feb;22(1):14791641251318309. doi: 10.1177/14791641251318309.

Abstract

BACKGROUND

This study aimed to investigate the effects of oral semaglutide on the changes in food preference of Japanese patients with type 2 diabetes.

METHODS

This retrospective multicenter study included 75 patients with type 2 diabetes who received oral semaglutide. The primary outcome was the change in the score of brief-type self-administered diet history questionnaire (BDHQ) score 3 months after the initiation of oral semaglutide treatment. The secondary outcome was the change in the Control of Eating Questionnaire (CoEQ), HbA1c, and body mass index (BMI) after 3 months.

RESULTS

The median age, BMI, and HbA1c of the 23 participants were 64.0 years, 26.9 kg/m, and 7.6% (59 mmol/mol). The BDHQ results showed total energy was significantly reduced. Among the individual nutrients, carbohydrates most decreased. The CoEQ results particularly showed declines in cravings for something sweet, chocolate or chocolate flavored foods, and starchy foods, satisfaction at meals, frequency and intensity of food craving, difficulty of resisting the craving for food, and frequency of eating in response to cravings for food were significantly lower after 3 months. The mean HbA1c and BMI significantly decreased.

CONCLUSIONS

In Japanese patients with type 2 diabetes, oral semaglutide treatment decreased total energy intake and changed food preferences.

摘要

背景

本研究旨在调查口服司美格鲁肽对日本2型糖尿病患者食物偏好变化的影响。

方法

这项回顾性多中心研究纳入了75例接受口服司美格鲁肽治疗的2型糖尿病患者。主要结局是口服司美格鲁肽治疗开始3个月后简易自填式饮食史问卷(BDHQ)得分的变化。次要结局是3个月后饮食控制问卷(CoEQ)、糖化血红蛋白(HbA1c)和体重指数(BMI)的变化。

结果

23名参与者的年龄中位数、BMI和HbA1c分别为64.0岁、26.9kg/m²和7.6%(59mmol/mol)。BDHQ结果显示总能量显著降低。在单一营养素中,碳水化合物减少最多。CoEQ结果特别显示,3个月后,对甜食、巧克力或巧克力味食物以及淀粉类食物的渴望、进餐满意度、食物渴望的频率和强度、抵抗食物渴望的难度以及因食物渴望而进食的频率均显著降低。平均HbA1c和BMI显著下降。

结论

在日本2型糖尿病患者中,口服司美格鲁肽治疗可降低总能量摄入并改变食物偏好。

相似文献

9
Efficacy of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus and its Impact on C-Peptide Levels.
Horm Metab Res. 2025 Jun;57(6):378-384. doi: 10.1055/a-2618-7509. Epub 2025 Jun 5.

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验